0848 ET - Citi downgrades Merck to neutral from buy amid concerns about the drugmaker's plans to address the 2028 loss of patent exclusivity for its blockbuster cancer drug Keytruda. In a note, Citi says that while headwinds from the exclusivity loss are well-appreciated, offsets from Merck's pipeline progression and new launches are taking time, and that Merck seems to have less urgency toward big M&A to offset looming Keytruda declines. Citi says a commercial-stage deal topping $10 billion could provide some relief to Merck shares, but the analysts say they think resolution of policy uncertainties around tariffs and most-favored-nation pricing are a higher priority for Merck. Citi cuts its Merck target price to $84 from $115. (colin.kellaher@wsj.com)
(END) Dow Jones Newswires
May 14, 2025 08:48 ET (12:48 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。